C12Y 304/21006
Coagulation factor xa
Official title: Coagulation factor Xa (3.4.21.6)
C12Y304/21006 (Coagulation factor xa) appears on 142 US grants and 212 published applications in this corpus.
Search patents in C12Y- Granted patents
- 142
- Published applications
- 212
- Assignees
- 103
- Inventors
- 290
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 6 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 8 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 5 |
| 2003 | 6 | 20 |
| 2004 | 3 | 10 |
| 2005 | 3 | 8 |
| 2006 | 2 | 3 |
| 2007 | 3 | 2 |
| 2008 | 3 | 8 |
| 2009 | 0 | 11 |
| 2010 | 8 | 7 |
| 2011 | 1 | 5 |
| 2012 | 8 | 9 |
| 2013 | 5 | 4 |
| 2014 | 7 | 10 |
| 2015 | 5 | 14 |
| 2016 | 8 | 17 |
| 2017 | 8 | 12 |
| 2018 | 5 | 11 |
| 2019 | 6 | 10 |
| 2020 | 11 | 11 |
| 2021 | 6 | 10 |
| 2022 | 3 | 9 |
| 2023 | 1 | 2 |
| 2024 | 2 | 4 |
| 2025 | 2 | 8 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating intracranial hemorrhage and assessing efficacy21 Jul 2026US 12,685,763 B2Alexion Pharmaceuticals, Inc.
- FX activation process and its use in the preparation of a FXa composition15 Apr 2025US 12,274,738 B2Octapharma AG
- Antidotes to factor XA inhibitors14 Jan 2025US 12,195,774 B2Alexion Pharmaceuticals, Inc.
- Prohemostatic proteins for the treatment of bleeding10 Sep 2024US 12,083,170 B2Academisch Ziekenhuis Leiden
- Lyophilized formulations for factor XA antidote11 Jun 2024US 12,005,144 B2Alexion Pharmaceuticals, Inc.
- Combined use of bispecific antibody binding to activated coagulation factor ix and coagulation factor x with blood coagulation factor x for treating subject with hemophilia a1 Oct 2026US 2026/0295022 A1KM Biologics Co., Ltd.
- Treatment of hemophilia a with fitusiran2 Jul 2026US 2026/0185097 A1Genzyme Corporation
- Modified factor xa polypeptides and methods of use2 Oct 2025US 2025/0302927 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Coagulation factor x activating enzyme and use thereof14 Aug 2025US 2025/0257347 A1Beijing Solobio Genetechnology Company Ltd.
- Fx activation process and its use in the preparation of a fxa composition10 Jul 2025US 2025/0222079 A1Octapharma AG
Most cited
By later US patents
- Pharmaceutical preparation for treating blood coagulation disorders81US 6,224,862 B1Baxter Aktiengesellschaft · 2001
- Antithrombosis agents64US 5,278,144 ACOR Therapeutics, Inc. · 1994
- Interative method of at least three cycles for the refolding of proteins41US 5,739,281 ADenzyme APS · 1998
- Iterative method of at least five cycles for the refolding of proteins38US 5,917,018 ADenzyme APS · 1999
- Chimeric serine proteases37US 6,660,492 B1Boehringer Mannheim GmbH · 2003